News | November 22, 2011

Propaten Vascular Graft Shows Excellent Patency Rates in Lower Extremity Bypass

November 22, 2011 — The question remains whether patency rates for heparin-bonded polytetrafluoroethylene (PTFE) grafts are better than traditional PTFE bypasses; whether these types of grafts should be used in all lower extremity bypass situations is also a question.

These questions were addressed at the 38th annual VEITH Symposium in New York City. Edward Y. Woo, M.D., associate professor of surgery, division of vascular surgery and endovascular therapy of Hospital of the University of Pennsylvania, made the presentation.

Lower extremity bypasses fail for a large number of reasons; the prominent ones include thrombus formation, progression of vascular disease, and intimal hyperplasia. Prosthetic grafts coated with heparin have been suggested as a possible way to address the mechanisms that lead to graft failure.

Woo reviewed the data around the Gore Propaten Vascular Graft. This graft has the Carmeda BioActive Surface heparin immobilization that allows for long-term heparin binding. Sustained heparin bioactivity has been shown in graft explants from an in vivo canine model after 12 weeks and a human graft explant out to three years.

Woo recently published a study that demonstrated excellent rates of patency for the Propaten graft in all positions. The rates surpassed historical patency rates for traditional PTFE grafts. However, Woo said, “There are some precautions to keep in mind. In patients who have heparin-induced thrombocytopenia (HIT), these grafts should not be used as the presence of heparin on the graft will worsen the HIT. In patients who demonstrate HIT after the procedure or have a suspicion of HIT, the management is more difficult.”

“The decision of explanting a Propaten graft in a patient that develops HIT will have to be made on a case by case basis,” concluded Woo.

Woo reported that he moved to using Propaten grafts in all positions where PTFE would be placed because of the improved patency rates.

For more information: www.veithpress.org

Related Content

Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.

Abbott says the Xience fluoropolymer coating interacts with blood proteins in a manner that reduces thrombus formation. This feature makes the stent safer to use for shorter duration DAPT.
 

News | Stents | June 30, 2021
June 30, 2021 — Abbott announced its Xience family of drug-eluting...
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.

The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and shape to the vessel and its movement.

News | Stents | April 14, 2021
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the...
Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

Comparison showing platelet adhesion to the surface of various coronary artery drug-eluting stents (DES) in a preclinical study that used aspirin only. Abbott said the Xience stent's fluoropolymer is significantly more anti-thrombotic than other DES.[2] 

News | Stents | April 06, 2021
April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual a
The stent struts of the Biotronik Orsiro stent.
News | Stents | December 21, 2020
December 21, 2020 – A proposed ASTM International standard will answer the need for a standardized test method that a
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.

News | Stents | November 24, 2020
November 24, 2020 — One-year results off the...
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS  study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates.

Feature | Stents | October 22, 2020 | Dave Fornell, Editor
October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durab
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents | October 22, 2020
October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnolog
The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

The FDA has cleared a new indication for the Medtronic Resolute Onyx Drug Eluting Stent, making it the first DES that only required one month of dual antiplatelet therapy (DAPT) in patients who are considered high risk for bleeding complications.

News | Stents | October 01, 2020
October 1, 2020 — Medtronic has received U.S.
News | Stents | July 24, 2020
July 24, 2020 — CeloNova BioSciences Inc.
Coronary and Peripheral Stent Market Expected to Double Through 2025
News | Stents | May 28, 2020
May 28, 2020 — The rising incidence of cardiovascular disease has prompted people to seek timely treatment to improve